Hence, in light of the involvement of ghrelin signalling and eEF2 in obesity, diabetes and carcinogenesis [28–32], the control of eEF2 phosphorylation upon activation of GHS-R1α emerges as an attractive therapeutic strategy. This evidence concerns the gene EEF2 and obesity due to melanocortin 4 receptor deficiency.